The Role of CCL22 and CCL5 in Gastric Tumor Cell Metastasis

Abstract

Author(s): Asraa Naduhm Abd-Alsatar1, Israa A Dheeb2

Background: Gastric cancer is single of the greatest complex types
of tumor in Iraq, because it is usually diagnosed late later the tumor
takes extent to additional portions of the body. To the identification of
some immunological indicators and their part in the development of
cancer, the existing training stood conducted to evaluate CCL22 and
CCL5 immune histologically and determine their role in metastasis of
GC.
Methods: Serum concentrations of CCL22 and CCL5 were
determined in cases of GC after and before tumor eradication using
ELISA kits, and the examination was carried out rendering to the
constructer's commands, while those indicators stood determined in
paraffin-embedded blocks of stomach tissues immune histologically
using the Immunohistochemistry (IHC) method.
Results: present study included 40 cases of GC with age mean of
55.3 years and most of patients are males (60%). We found most of
the patients in the fourth (70%) and third stages (25%), in which the
cancer is considered to be in the advanced stage. IHC assay
determine that CCL22 and CCL5 are highly expressed in gastric
cancer cells. Serologically, CCL22 and CCL5 were significantly higher
(p<0.05) among cases before surgery (19.38 and 21.41 pg/ml) than
after surgery (5.01and 6.79 pg/ml) and healthy controls (0.628, 5.053,
6.181 and 7.22 pg/ml) (p<0.05). This study found the highest
concentration of CCL5 after and before surgery in advanced
metastatic cancer cases (stage IV) while the highest level of CCL22
appeared in patients in stage III.
Conclusion: we determined that CCL22 and CCL5 are associated
histologically and immunologically with GC, which could be indicators
for GC metastases and a target for its treatment.

Share this article